Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Core Viewpoint - Kiniksa Pharmaceuticals will participate in the 2024 Wells Fargo Healthcare Conference, indicating ongoing engagement with investors and the healthcare community [1]. Company Overview - Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapeutic medicines for patients with significant unmet medical needs [3]. - The company’s immune-modulating assets include ARCALYST®, abiprubart, and mavrilimumab, which target underserved cardiovascular and autoimmune conditions [3]. - Kiniksa aims to differentiate its products based on strong biological rationale and validated mechanisms [3]. Event Details - The fireside chat is scheduled for September 4, 2024, at 8:00 a.m. Eastern Time, showcasing the company's commitment to transparency and investor relations [1]. - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours post-event [2].